EMA Authorised: Erivedge (vismodegib) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Erivedge (vismodegib) by Roche Registration GmbH for basal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Erivedge (vismodegib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Basal Cell. MAH: Roche Registration GmbH. Decision date: 04/11/2025